Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference
February 22, 2021 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients
February 17, 2021 07:30 ET
|
Salarius Pharmaceuticals, Inc.
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. ...
Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference
February 16, 2021 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
January 21, 2021 08:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference
January 15, 2021 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
January 13, 2021 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"
December 22, 2020 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid...
Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat
December 11, 2020 11:32 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
December 10, 2020 09:28 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium
November 17, 2020 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...